EV-derived GClnc1 effectively distinguished early-stage GC from precancerous lesions (chronic atrophic gastritis and intestinal metaplasia) and GC with negative traditional gastrointestinal biomarkers (CEA, CA72-4, and CA19-9). The gene discussed is SOD2; the disease is gastric cancer.